Literature DB >> 1480144

Release of heart fatty acid-binding protein into plasma after acute myocardial infarction in man.

A H Kleine1, J F Glatz, F A Van Nieuwenhoven, G J Van der Vusse.   

Abstract

The release of cytoplasmic heart fatty acid-binding protein (H-FABP) into the plasma of cardiac patients up to 38 hr after the onset of the first clinical symptoms of acute myocardial infarction (AMI) was studied, using a sensitive direct and noncompetitive Enzyme Linked Immunosorbent Assay of the antigen capture type (sandwich ELISA), newly developed for the measurement of small amounts of human H-FABP in plasma samples. Plasma levels of H-FABP were compared with plasma activity levels of the myocardial cytoplasmic enzymes creatine kinase MB (CK-MB) and alpha-hydroxybutyrate dehydrogenase (alpha-HBDH). Upper normal levels of H-FABP (19 micrograms/l), CK-MB (10 U/l) and alpha-HBDH (160 U/l) as determined in plasma from 72 blood donors served as threshold levels. H-FABP levels were significantly elevated above their threshold level within 3 hr after AMI. Peak levels of H-FABP, CK-MB and alpha-HBDH were reached 4.1 +/- 0.9 hr, 8.4 +/- 1.4 hr and 25.0 +/- 9.5 hr (means +/- S.D., n = 10) after acute myocardial infarction, respectively. Serial time curves of the plasma contents of H-FABP reveal that after myocardial infarction H-FABP is released in substantial amounts from human hearts. In 18 out of 22 patients with established AMI the plasma FABP level was at or above the threshold level in blood-samples taken within 3.5 hr after the first onset of symptoms of AMI, while for CK-MB this applied to 9 patients and for alpha-HBDH to 6 patients. These findings suggest that for an early indication of acute myocardial infarction in man cytoplasmic heart fatty acid-binding protein is more suitable than heart type creatine kinase MB and/or alpha-hydroxybutyrate dehydrogenase.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1480144     DOI: 10.1007/bf01270583

Source DB:  PubMed          Journal:  Mol Cell Biochem        ISSN: 0300-8177            Impact factor:   3.396


  26 in total

1.  Reduction of alpha-ketobutyrate by human serum.

Authors:  S B ROSALKI; J H WILKINSON
Journal:  Nature       Date:  1960-12-24       Impact factor: 49.962

Review 2.  Cellular fatty acid-binding proteins: current concepts and future directions.

Authors:  J F Glatz; G J van der Vusse
Journal:  Mol Cell Biochem       Date:  1990 Oct 15-Nov 8       Impact factor: 3.396

Review 3.  Structural and functional features of different types of cytoplasmic fatty acid-binding proteins.

Authors:  J H Veerkamp; R A Peeters; R G Maatman
Journal:  Biochim Biophys Acta       Date:  1991-01-04

4.  Type-specific immunodetection of human heart fatty acid-binding protein with polyclonal anti-peptide antibodies.

Authors:  A H Kleine; J F Glatz; F A van Nieuwenhoven; M I Vallinga; M H Salden; F T Bosman; W J Boersma; N D Zegers; G J van der Vusse
Journal:  Mol Cell Biochem       Date:  1990 Oct 15-Nov 8       Impact factor: 3.396

5.  Immunochemical quantitation of fatty acid-binding proteins. Tissue distribution of liver and heart FABP types in human and porcine tissues.

Authors:  R J Paulussen; H T van Moerkerk; J H Veerkamp
Journal:  Int J Biochem       Date:  1990

6.  Myoglobin and creatine kinase in acute myocardial infarction.

Authors:  J M McComb; E A McMaster; G MacKenzie; A A Adgey
Journal:  Br Heart J       Date:  1984-02

7.  Myoglobin content in human skeletal muscle and myocardium: relation to fibre size and oxidative capacity.

Authors:  C Sylvén; E Jansson; K Böök
Journal:  Cardiovasc Res       Date:  1984-07       Impact factor: 10.787

8.  Myoglobinemia in the early phase of acute myocardial infarction.

Authors:  H Drexel; E Dworzak; W Kirchmair; M M Milz; B Puschendorf; F Dienstl
Journal:  Am Heart J       Date:  1983-04       Impact factor: 4.749

9.  Serum myoglobin levels in patients with ischemic myocardial insult.

Authors:  A Isakov; I Shapira; M Burke; C Almog
Journal:  Arch Intern Med       Date:  1988-08

10.  Early detection of acute myocardial infarction: additional diagnostic information from serum concentrations of myoglobin in patients without ST elevation.

Authors:  E M Ohman; C Casey; J R Bengtson; D Pryor; W Tormey; J H Horgan
Journal:  Br Heart J       Date:  1990-06
View more
  54 in total

1.  Heart-type fatty acid binding protein is an independent predictor of death and ventricular dysfunction after coronary artery bypass graft surgery.

Authors:  Jochen D Muehlschlegel; Tjörvi E Perry; Kuang-Yu Liu; Amanda A Fox; Charles D Collard; Stanton K Shernan; Simon C Body
Journal:  Anesth Analg       Date:  2010-05-10       Impact factor: 5.108

2.  Heart-type, fatty-acid binding protein can be a diagnostic marker in acute coronary syndromes.

Authors:  Umut Cavus; Figen Coskun; Bunyamin Yavuz; Orcun Ciftci; Levent Sahiner; Hakan Aksoy; Ali Deniz; Engin Ozakin; Kudret Aytemir; Lale Tokgozoglu; Giray Kabakci
Journal:  J Natl Med Assoc       Date:  2006-07       Impact factor: 1.798

3.  Vasculo-protective effect of BMS-309403 is independent of its specific inhibition of fatty acid-binding protein 4.

Authors:  Yuta Okamura; Kosuke Otani; Akihiro Sekiguchi; Taisuke Kogane; Chiharu Kakuda; Yuzaburo Sakamoto; Tomoko Kodama; Muneyoshi Okada; Hideyuki Yamawaki
Journal:  Pflugers Arch       Date:  2017-04-13       Impact factor: 3.657

4.  Human heart-type cytoplasmic fatty acid-binding protein as an indicator of acute myocardial infarction.

Authors:  K Yoshimoto; T Tanaka; K Somiya; R Tsuji; F Okamoto; K Kawamura; Y Ohkaru; K Asayama; H Ishii
Journal:  Heart Vessels       Date:  1995       Impact factor: 2.037

Review 5.  Candidate-based proteomics in the search for biomarkers of cardiovascular disease.

Authors:  Leigh Anderson
Journal:  J Physiol       Date:  2004-12-20       Impact factor: 5.182

6.  Overexpression of FABP3 inhibits human bone marrow derived mesenchymal stem cell proliferation but enhances their survival in hypoxia.

Authors:  Suna Wang; Yifu Zhou; Oleg Andreyev; Robert F Hoyt; Avneesh Singh; Timothy Hunt; Keith A Horvath
Journal:  Exp Cell Res       Date:  2014-02-27       Impact factor: 3.905

7.  Evaluation of the diagnostic performance of heart-type fatty acid binding protein in the BWH-TIMI ED chest pain study.

Authors:  Christian T Ruff; Marc P Bonaca; Joshua M Kosowsky; Michael J Conrad; Sabina A Murphy; Petr Jarolim; Sean M Donahoe; Michelle L O'Donoghue; David A Morrow
Journal:  J Thromb Thrombolysis       Date:  2013-11       Impact factor: 2.300

8.  Increased H-FABP concentrations in nonalcoholic fatty liver disease. Possible marker for subclinical myocardial damage and subclinical atherosclerosis.

Authors:  O Başar; E Akbal; S Köklü; Y Tuna; E Koçak; N Başar; D Tok; H Erbiş; M Senes
Journal:  Herz       Date:  2013-01-18       Impact factor: 1.443

9.  Prognostic value of combination of heart-type fatty acid-binding protein and ischemia-modified albumin in patients with acute coronary syndromes and normal troponin T values.

Authors:  Cui Liyan; Zhang Jie; Hu Xiaozhou
Journal:  J Clin Lab Anal       Date:  2009       Impact factor: 2.352

10.  Acute regional left atrial ischemia causes acceleration of atrial drivers during atrial fibrillation.

Authors:  Masatoshi Yamazaki; Uma Mahesh R Avula; Krishna Bandaru; Auras Atreya; Venkata Subbarao C Boppana; Haruo Honjo; Itsuo Kodama; Kaichiro Kamiya; Jérôme Kalifa
Journal:  Heart Rhythm       Date:  2013-02-21       Impact factor: 6.343

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.